MARS Automation Platform for Biopharma
Quartica, Inc. · Intelligence & Research
Certification per Microsoft Marketplace.
Evidence tier Source Confirmed · 8 captures on record
What the publisher says
As described on Microsoft Marketplace.
To stay competitive in the post-covid changing market with shorter R&D cycle times, a key differentiator for biopharma companies is the ability to create content (documents, reports, scorecards, schedules, signals, summaries, letters, etc.) with insights and evidence from multiple data sources quickly and with quality and regulatory compliance. MARS enables biopharma companies to bring the ad-hoc facets of content generation and analytics across the biopharma value chain using AI.
MARS improves the information flow enabling new content creation business models which can provide better patient engagement and experience to biopharma companies. MARS enterprise content generation can help improve the end-to-end process from information flow, content creation, insights to the distribution and tracking of compliance metrics.
Show the rest of the publisher’s description (37 more lines)
Key Features:
- Automated text narratives, data analysis with tables and figures in compliance with regulations (ICH, GVP and others)
- Automated analysis of clinical & safety data with data insights and trends
- Automated document generation from multiple libraries and data
sources
- Automated abbreviations list and references list including shared and re-usable lists
- Collaborative authoring and review with AI as co-author
- Content tense adjustment and harmonization
- Artificial Intelligence / Machine Learning capabilities
- Out of the box and Customizable API's
- Configurable workflows, templates, notifications and task management
- 21 CFR Part 11 compliant with audit trails with blinded and unblinded user profiles
MARS Key Use Cases across the biopharma value chain:
- Pharmacovigilance (Safety)
- Aggregate Reports
- Safety Data Analysis
- Signal Management
- Risk Management
- SDEA, QPPV & Others
- Clinical and Medical Affairs
- Clinical Protocols
- Clinical Study Reports
- Investigator Letters (DILs)
- Standard Query Responses
- Others
- Regulatory Affairs
- Regulatory eCTD
- Regulatory Intelligence
- Labeling
- CMC Change Assessments
- Others
- Manufacturing & Quality
- Annual Product Review
- Training & Upskilling
- Protocol Verification
- Quality Documents
- Others
Preview
3 images
Agent build and provenance
See the full provenance
The layer-by-layer build, the evidence behind each claim, the risk basis and the cross-marketplace links are open to any account. Some rows are disclosed, some the source leaves Unknown; a free account shows you which.
Compliance
- FedRAMPConfirmedNot listed90%, registry-checkedNo FedRAMP Marketplace entry matched this vendor's domain, checked 2026-08-27registry recordas observed 2026-08-27
Confirmed means matched to a public authoritative registry. Claimed means the vendor or its listing states it, not yet cross-checked. A framework not shown was not found in any source we hold, which is not evidence against it. Not listed means a scoped registry check found no match for this vendor's domain: a No is a scoped registry check, not a compliance judgment. Confidence bands: 95% domain-verified, 90% registry-checked, 80% self-attested, 70% weak signal. Self-attested items marked “vendor's site” are gathered from the vendor's own website and are not verified by us.
Vendor
External enrichment
Sources
Publisher resources
8 linksLinked repositories
Unknown means this listing does not publish a repository. It is not a statement that the code is closed, and a linked repository is not a claim that the publisher wrote it: the registry computes that relationship privately and does not publish it.
Evidence risk is the share of the build you cannot see before you deploy, not a security rating. Sign in to see the layer-by-layer basis for this band.